Eisai Listed for 18th Consecutive Year in FTSE4Good Index Series

Jul 11, 2019 13:59 JST

Source: Eisai

An Index for Socially Responsible Investment
Eisai

TOKYO, Jul 11, 2019 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has been included in the FTSE4Good Index Series for the 18th consecutive year since its initial inclusion in 2002.

The FTSE4Good Index Series is a global index series for socially responsible investment.

The FTSE4Good Index Series is designed to help investors integrate the global standard factors of environmental, social and governance (ESG) into their investment decisions. Eisai received particularly high scores in "Customer Responsibility", "Labor Standards", "Corporate governance", "Anti-Corruption", and "Climate Change", among others. As of July 2019, a total of 1,034 companies from around the world have been selected for the FTSE4Good Developed Index, including 175 companies from Japan.

Along with being listed in the FTSE4Good Index Series, Eisai is also listed in the MSCI Japan Empowering Women Index (WIN), the FTSE Blossom Japan Index, the MSCI Japan ESG Select Leaders Index, and S&P/JPX Carbon Efficient Index, which are the four ESG investment indices for Japanese stocks adopted by the Government Pension Investment Fund (GPIF).

Eisai's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides as well as address diverse healthcare needs worldwide. By strengthening its ESG initiatives and increasing non-financial value, Eisai is striving to sustainably enhance corporate value based on this corporate philosophy.

Contact:

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

Source: Eisai
Sectors: BioTech

Related Press Release

LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025"

October 14 2025 16:54 JST

Eisai and Biogen Announce U.S. Availability of LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease

October 08 2025 11:03 JST

Eisai Highlights Breadth of Oncology Research at ESMO 2025

October 03 2025 17:01 JST

"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in China

September 29 2025 09:33 JST

LEQEMBI(R) (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Australia

September 24 2025 18:04 JST

Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation

September 17 2025 17:20 JST

"New Answers to Dementia" Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month

September 12 2025 12:20 JST

Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025

September 08 2025 16:49 JST

Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025

September 04 2025 09:56 JST

Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status

September 03 2025 10:32 JST

More Press release >>

Latest Press Release

Mitsubishi Motors Wins Triple Honors at Good Design Award 2025 in Japan with the Delica Mini, Destinator and Delica Series
Oct 15, 2025 21:29 JST

Mitsubishi Motors at Japan Mobility Show 2025: World Premiere of Electrified Crossover SUV Concept
Oct 15, 2025 20:35 JST

Honda to Present World Premiere of ProZision(TM) Autonomous, at Equip Exposition 2025, Honda Battery-powered Autonomous Riding Lawn Mower
Oct 15, 2025 19:56 JST

Honda to Make Additional Investment in U.S.-based Helm.ai to Further Enhance Development of Next-generation AD/ADAS
Oct 15, 2025 19:25 JST

MHI Thermal Systems Wins 2025 GOOD DESIGN AWARD for Hyper Multi LXZ Series of Building-Use Multi-Split Air-Conditioners in Japan
Oct 15, 2025 18:50 JST

Mitsubishi Power Marks 60 Years in Saudi Arabia with Unveiling of First Locally Assembled JAC Gas Turbine at Dammam Assembly Facility
Oct 14, 2025 18:21 JST

LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025"
Oct 14, 2025 17:54 JST

Mazda Announces Exhibition at JAPAN MOBILITY SHOW 2025
Oct 14, 2025 17:38 JST

Hitachi Advances Strategic Alliance with Google Cloud to Empower Frontline Workers with Field-Specific AI Agents
Oct 11, 2025 00:58 JST

Honda Issues Integrated Report - "Honda Report 2025"
Oct 11, 2025 00:46 JST

DENSO's Electrification Products Adopted for TOYOTA's New "bZ4X"
Oct 11, 2025 00:21 JST

Newly developed eAxle adopted for TOYOTA's new "bZ4X"
Oct 11, 2025 00:08 JST

MHIET and MHI-TC Complete Delivery of First "COORDY" Controller Providing Optimized Control of Multiple Power Sources
Oct 10, 2025 23:47 JST

Fujitsu migrates service operations virtualization platform used by 3,000 companies to Nutanix and introduces migration support services utilizing proven expertise
Oct 10, 2025 23:25 JST

Anime Tokyo Station: TV Anime 'SPYxFAMILY' Special Exhibition, New Designs Added for Admission Bonus Illustration Cards
Oct 10, 2025 11:30 JST

TANAKA to Provide Medals Expressing Every Runner's Trail through Flowing Curves for the Tokyo Legacy Half Marathon 2025
Oct 10, 2025 03:00 JST

Genequest and Fujitsu uncover new insights into genetics-lifestyle relationships through high-speed, reliable causal AI from Fujitsu Kozuchi
Oct 10, 2025 00:55 JST

Sharp Launches A3 MFPs (BP Series)
Oct 10, 2025 00:50 JST

Mitsubishi Shipbuilding Holds Christening and Launch Ceremony in Shimonoseki for Large Car Ferry HAMANASU
Oct 10, 2025 00:42 JST

Honda Celebrates 30th Anniversary of CR-V
Oct 09, 2025 23:54 JST

More Latest Release >>